Clinical trial drug management system and method based on traceability
Through sample traceability labels and real-time traceability models, the data incompleteness and errors caused by manual recording in the drug management system for clinical trials are solved, real-time monitoring of drug status and data reliability are achieved, and the transparency and traceability of the experiment are improved. sex.
Patent Information
- Application Number
- CN202411282654.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-13
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-09-13
AI Technical Summary
The existing drug management system for clinical trials relies on manual records, resulting in incomplete data and frequent errors, and the inability to trace the status and flow of drugs in real time, affecting the trial results and patient safety.
An automated system based on sample traceability tags and real-time traceability models is adopted to obtain drug sample information, generate and update sample traceability tags, monitor and analyze drug status in real time, and dynamically manage tag content to ensure data accuracy and traceability.
Reduce manual entry errors, improve data reliability and trial transparency, ensure traceability and compliance of drugs throughout the trial process, promptly obtain the latest trial data and progress, and support trial management and decision-making.
Smart Images

Figure CN118800390B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of data processing, and in particular to a drug management system and method for clinical trials based on traceability. Background Art
[0002] With the rapid development of the pharmaceutical industry, clinical trials play a vital role in the development and marketing of new drugs. The management of drugs used in clinical trials involves multiple links, including drug production, packaging, distribution, storage, use, and waste disposal. Problems in any link may affect the results of clinical trials and even pose a threat to patient safety. Therefore, how to ensure the traceability, transparency, and compliance of drugs throughout the clinical trial process has become a key issue in the drug management system.
[0003] In the existing technology, traditional clinical trial drug management mostly relies on manual records and manual supervision, which has many limitations. Manual records are prone to omissions and errors, resulting in incomplete drug management data. When problems occur with drugs, it is impossible to quickly and accurately trace the production batch, circulation process, and final use of the drugs, which increases the complexity of problem solving. The manual management model is inefficient and it is difficult to grasp the status and flow of drugs in real time, affecting the smooth progress of clinical trials. Environmental conditions (such as temperature and humidity) during drug storage and transportation cannot be monitored in real time, which may lead to a decline in drug quality and thus affect the test results.
[0004] Therefore, it is urgent to design a technical solution to solve the above technical problems. Summary of the invention
[0005] In view of the technical problems existing in the prior art, the present invention provides a drug management system and method based on traceability for clinical trials, which is used to automatically generate sample traceability labels and data records through sample traceability labels and real-time traceability models, reduce errors that may be caused by manual data entry, improve data reliability, and improve the transparency and traceability of the trial process.
[0006] In a first aspect, an embodiment of the present application provides a method for managing drugs for clinical trials based on traceability, the method comprising:
[0007] Obtain sample information of the target drug; the sample information includes at least: drug name, clinical trial information, test information, and drug production information;
[0008] Generate a corresponding sample traceability label based on the sample information; the sample traceability label is at least used to record the sample distribution and real-time test status of the drug test;
[0009] Monitor the real-time test status of the target drug; the real-time test status is used to indicate the current progress of the test of the target drug during the clinical trial and real-time test process data;
[0010] A real-time traceability model is used to analyze the real-time test status, and the sample traceability label is dynamically updated and / or remotely managed to ensure that the user obtains the real-time test progress of the target drug.
[0011] In a second aspect, the embodiment of the present application provides a drug management system for clinical trials based on traceability, the system comprising the following units, wherein:
[0012] An acquisition unit is configured to acquire sample information of a target drug; the sample information at least includes: drug name, clinical trial information, test information, and drug production information;
[0013] A generating unit is configured to generate a corresponding sample traceability label based on the sample information; the sample traceability label is at least used to record the sample distribution and real-time test status of the drug test;
[0014] A monitoring unit configured to monitor the real-time test status of the target drug; the real-time test status is used to indicate the current progress of the drug test and real-time test process data during the clinical trial;
[0015] The management unit is configured to analyze the real-time test status using a real-time traceability model, dynamically update and / or remotely manage the sample traceability label to ensure that the user obtains the real-time test progress of the target drug.
[0016] In a third aspect, an embodiment of the present application provides an electronic device, the electronic device comprising:
[0017] at least one processor, memory, and input-output unit;
[0018] The memory is used to store a computer program, and the processor is used to call the computer program stored in the memory to execute the first aspect of the clinical trial drug management method based on traceability.
[0019] In a fourth aspect, a computer-readable storage medium is provided, which includes instructions, and when the instructions are executed on a computer, the computer executes the traceability-based clinical trial drug management method of the first aspect.
[0020] The beneficial effect of the present invention is that a drug management system and method for clinical trials based on traceability are provided. In the technical scheme, first, the sample information of the target drug is obtained; the sample information at least includes: drug name, clinical trial information, test detection information, and drug production information. Then, a corresponding sample traceability label is generated based on the sample information; the sample traceability label is at least used to record the sample distribution of the drug test and the real-time test status. Next, the real-time test status of the target drug is monitored; the real-time test status is used to indicate the current progress of the drug test and the real-time test process data during the clinical trial. Finally, the real-time traceability model is used to analyze the real-time test status, dynamically update and / or remotely manage the sample traceability label to ensure that the user obtains the real-time test progress of the target drug. In the technical scheme, the sample traceability label and data record are automatically generated through the sample traceability label and the real-time traceability model, reducing the errors that may be caused by manual data entry and improving the reliability of the data. In addition, by analyzing the real-time test status through the real-time traceability model, the information on the sample traceability label can be dynamically updated, which helps to obtain the latest test data and progress in a timely manner and improve the transparency and traceability of the test process. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 It is a flow chart of a method for managing drugs for clinical trials based on traceability according to an embodiment of the present application;
[0022] Figure 2 This is a schematic diagram of the structure of a drug management system for clinical trials based on traceability according to an embodiment of the present application;
[0023] Figure 3 is a schematic diagram of the structure of an electronic device according to an embodiment of the present application;
[0024] Figure 4 It is a structural schematic diagram of a medium device according to an embodiment of the present application. DETAILED DESCRIPTION
[0025] The following will be combined with the drawings in the embodiments of the present application to clearly and completely describe the technical solutions in the embodiments of the present application. Obviously, the described embodiments are only part of the embodiments of the present application, not all of the embodiments. Based on the embodiments in the present application, all other embodiments obtained by those skilled in the art without creative work are within the scope of protection of this application.
[0026] In the description of this application, the terms "first" and "second" are used for descriptive purposes only and should not be understood as indicating or implying relative importance or implicitly indicating the number of technical features indicated. Thus, a feature defined as "first" or "second" may explicitly or implicitly include one or more of the features. In the description of this application, "plurality" means two or more, unless otherwise clearly and specifically defined.
[0027] In the description of the present application, the term "for example" is used to mean "used as an example, illustration or description". Any embodiment described as "for example" in the present application is not necessarily to be construed as being more preferred or advantageous than other embodiments. The following description is given to enable any technician in the field to implement and use the present invention. In the following description, details are listed for the purpose of explanation. It should be understood that a person of ordinary skill in the art can recognize that the present invention can be implemented without using these specific details. In other examples, well-known structures and processes will not be elaborated in detail to avoid unnecessary details to obscure the description of the present invention. Therefore, the present invention is not intended to be limited to the embodiments shown, but is consistent with the widest scope consistent with the principles and features disclosed in the present application.
[0028] The embodiment of the present application provides a clinical trial drug management system and method based on traceability. In this technical solution, first, the sample information of the target drug is obtained; the sample information includes at least: drug name, clinical trial information, test detection information, and drug production information. Then, a corresponding sample traceability label is generated based on the sample information; the sample traceability label is at least used to record the sample distribution of the drug trial and the real-time test status. Next, the real-time test status of the target drug is monitored; the real-time test status is used to indicate the current progress of the drug trial and real-time test process data during the clinical trial. Finally, the real-time traceability model is used to analyze the real-time test status, and the sample traceability label is dynamically updated and / or remotely managed to ensure that the user obtains the real-time test progress of the target drug.
[0029] In the embodiment of the present application, sample traceability labels and data records are automatically generated through sample traceability labels and real-time traceability models, reducing errors that may be caused by manual data entry and improving data reliability. Specifically, the complete historical record of the test data is retained to facilitate subsequent audits and analysis, ensuring the traceability and compliance of the test process.
[0030] In addition, in the embodiments of the present application, by analyzing the real-time test status through the real-time traceability model, the information on the sample traceability label can be dynamically updated, which helps to obtain the latest test data and progress in a timely manner and improve the transparency and traceability of the test process. Specifically, by analyzing and predicting the progress of the test, it can provide valuable reference for future test planning and strategy adjustments. By analyzing the test data through the real-time traceability model, potential safety issues can be discovered in advance and corresponding preventive measures can be taken.
[0031] The traceable clinical trial drug management scheme provided in the embodiments of the present application can also be executed by an electronic device, which can be a server, a server cluster, or a cloud server. The electronic device can also be a terminal device such as a mobile phone, a computer, a tablet computer, a wearable device, or a dedicated device (such as a dedicated terminal device with a traceable clinical trial drug management system). These electronic devices can also be equipped with the chips introduced in the above embodiments. Alternatively, these electronic devices can also be installed with a service program for executing a traceable clinical trial drug management scheme.
[0032] Figure 1 A schematic diagram of a process for managing clinical trial drugs based on traceability provided in an embodiment of the present application is shown in FIG. Figure 1 As shown, the method comprises the following steps:
[0033] 101, obtaining sample information of target drugs;
[0034] 102, generating a corresponding sample traceability label based on the sample information;
[0035] 103, monitoring the real-time test status of the target drug;
[0036] 104. Analyze the real-time test status using a real-time traceability model, dynamically update and / or remotely manage the sample traceability label to ensure that the user obtains the real-time test progress of the target drug.
[0037] In an embodiment of the present application, the sample information includes at least: drug name, clinical trial information, test information, and drug production information. Before generating a sample traceability label, it is first necessary to obtain detailed sample information of the target drug. This information includes the specific name of the drug, which is used to identify the drug name of the drug; clinical trial information, including trial protocol, trial phase, participant information, and drug use plan, etc., to ensure that the use of drugs in clinical trials complies with the established plan; test information, covering the test standards, test methods, and results that need to be carried out during the trial of the drug to ensure the accuracy and reliability of the trial; drug production information, including manufacturer, production batch number, production date, and expiration date, etc., to ensure the traceability of the source of the drug and compliance with its use. The acquisition and integration of these detailed information is the basis for generating accurate and effective sample traceability labels.
[0038] In an embodiment of the present application, the sample traceability label is at least used to record the sample distribution of the drug trial and the real-time trial status. The sample traceability label records the distribution information of the drug in the clinical trial, including the distribution number, distribution time, distribution location, subject information and distribution personnel. The distribution number is the unique identification number of each sample in the trial, which is used to track the specific drug sample; the distribution time is the specific time when the drug sample is distributed to the subject or the trial center, ensuring that the time node of the trial is traceable; the distribution location records the location information where the sample is distributed, such as the hospital, trial center or laboratory, to ensure the traceability of the geographical location; the subject information is recorded in a coded form to protect the privacy of the subject and ensure the accuracy of the sample distribution; the distribution personnel information records the person responsible for the sample distribution to ensure that the responsibility is assigned to the person. The sample traceability label also records the real-time status of the drug trial, including the current status, environmental conditions, test results and status change records. Current statuses such as "in transit", "received", "in use", "under testing", etc. ensure transparency at every node in the test process; environmental conditions such as temperature and humidity of samples during storage or transportation are recorded in real time to ensure controllability of drug quality; test results update the test data of drug samples during the test in real time to ensure that the sample status is consistent with the test requirements; status change records record any status changes in detail for subsequent traceability and analysis. By recording the above content, the sample traceability label ensures the full traceability of drugs in clinical trials, not only can it monitor the use status of drugs in real time, but also can provide detailed records of sample distribution and status changes, providing guarantees for the effectiveness and safety of the test.
[0039] In the embodiment of the present application, the real-time test status is used to indicate the current progress of the test of the target drug during the clinical trial and the real-time test process data. In the embodiment of the present application, the real-time test status includes but is not limited to the following:
[0040] Real-time trial status indicates the current stage of progress of the target drug in clinical trials. The specific content includes: the current clinical trial stage of the drug, such as Phase I, Phase II or Phase III trials, so as to clearly understand the overall progress of the trial. The completion of key trial milestones, such as completion of subject recruitment, first medication, mid-term analysis, etc., provide real-time reference for trial management. The medication status of the subjects, including the number of subjects who have received the drug, the number of medications, etc., so as to understand the coverage and progress of the trial.
[0041] The real-time trial status also includes real-time data collected during the trial, the specific contents of which are as follows: drug usage, real-time recording of drug usage, such as medication time, dosage and frequency of use, to ensure that each subject's medication process complies with the trial plan; physiological monitoring data, physiological data of the subject after medication, such as real-time monitoring of important indicators such as blood pressure, heart rate, and blood sugar, to help evaluate the immediate effect and safety of the drug; side effect report, real-time recording and summary of any adverse reactions or side effects that the subject experiences during the trial, and timely analysis and response based on these data; drug storage and transportation status, real-time monitoring of the status of the drug during storage and transportation, including environmental conditions such as temperature and humidity, to ensure the quality stability of the drug throughout the trial.
[0042] In short, any change in the trial status will be updated and recorded in the system in real time, ensuring that every link in the trial process can be traced completely and accurately. The dynamic update of real-time trial status data not only helps the daily management of the trial, but also provides a reliable basis for the phased evaluation of the trial and the analysis of the final results. Through the indication and data recording of real-time trial status, the progress and status changes of the target drug in the clinical trial can be fully and timely grasped, thereby providing strong support for trial management and decision-making, ensuring the smooth progress of the trial and the reliability of the results.
[0043] In summary, in 101, the sample information of the target drug is obtained. In this step, the system first collects detailed sample information of the target drug. This information includes the name of the drug, production batch, production date, manufacturer, expiration date, and details related to the clinical trial, such as the trial stage, participant information, and drug use plan. The main purpose of this step is to ensure a complete understanding of the drug and provide data support for subsequent traceability management. In 102, the corresponding sample traceability label is generated based on the sample information. Once the sample information of the target drug is obtained, the system will generate the corresponding sample traceability label based on this information. This label contains all key information related to the drug, such as the drug's distribution information, production information, and use plan. The generated label is unique, ensuring that each drug sample can be accurately tracked and managed throughout the trial. In 103, the real-time trial status of the target drug is monitored. During the clinical trial, the system continuously monitors the real-time trial status of the target drug. The monitoring content includes the current trial stage of the drug, the subject's medication, the physiological data collected during the trial, and the environmental conditions for drug storage and transportation. Real-time monitoring ensures the accuracy and timeliness of the trial data and helps to discover and solve problems in the trial. In 104, a real-time traceability model is used to analyze the real-time test status, and dynamically update and / or remotely manage the sample traceability label. Specifically, the real-time traceability model is used to analyze the monitored real-time test status data. According to the analysis results, the information in the sample traceability label is dynamically updated, such as drug status changes, subject feedback, etc. In addition, the system can also adjust and update the sample traceability label through the remote management function to ensure that all relevant parties can obtain the latest drug test progress information in real time.
[0044] Through the above steps, users can obtain the latest progress of the target drug in clinical trials in real time. This not only improves the transparency and traceability of clinical trials, but also provides important decision-making basis for trial managers and related parties, ensuring the smooth progress of trials and the safety of drug use. The above steps complement each other and constitute a complete, traceability-based clinical trial drug management method to ensure accurate management and real-time tracking of drugs throughout the clinical trial process.
[0045] 101. Obtain sample information of target drugs. Specifically, when obtaining sample information of target drugs, first, it is necessary to collect basic information of drugs, such as drug name, specification, production batch, manufacturer, production date, expiration date, etc. This information is the basic data for drug traceability and management, ensuring that each sample can be accurately identified in the trial. In addition to basic information, specific information related to clinical trials needs to be obtained. This includes the trial phase of the drug (such as Phase I, Phase II, Phase III), trial protocol, trial design (such as randomized controlled, double-blind trial, etc.), sample distribution plan, etc. This information helps to effectively manage and track drugs at different stages of clinical trials. When collecting sample information, it is also necessary to associate relevant information of the subjects (usually recorded in coded form). This includes the subject number, the number and dosage of the distributed drugs, etc., so as to track the medication of each subject in the trial and protect their privacy. Obtaining storage conditions (such as temperature, humidity, etc.) and transportation information (such as transportation time, transportation conditions, etc.) of drug samples is crucial to ensuring drug quality. Ensure that the samples are always stored under appropriate conditions before being distributed to various trial centers or subjects. If the target drug has been used in other clinical trials before, its historical data needs to be integrated, including previous trial results, drug use records, related adverse reaction information, etc. These historical data can provide reference for the current trial and help optimize trial design and sample management.
[0046] As an optional embodiment, in 102, generating a corresponding sample traceability label based on the sample information may be implemented as follows:
[0047] 201, integrating the drug name, clinical trial information, test information, and drug production information in the sample information into a sample data set of the target drug;
[0048] 202, determining a label layout of the sample traceability label based on the sample information;
[0049] 203, extracting key information from the sample data set, and encoding the key information as initial sample information of the sample traceability label based on the label layout; the key information is associated with a drug test type; the key information is used to represent a key characteristic of a drug and / or a drug test characteristic;
[0050] 204 : Construct the sample traceability label based on the label layout and the initial sample information.
[0051] Exemplarily, first, the drug name, clinical trial information, test information, and drug production information in the sample information are integrated into a sample data set of the target drug. For example, the drug name is anticancer drug X, the clinical trial information is a phase III clinical trial, a randomized controlled, double-blind trial, the trial number is CT2024-001, the test information includes blood routine, liver function, and kidney function, and the test frequency is once every two weeks. The drug production information is the production batch number B12345, the production date is 2024-01-01, and the validity period is until 2026-01-01. Next, the label layout of the sample traceability label is determined based on the sample information, and the layout should include the display position and format of various types of information to ensure that the information is clear and easy to read. For example, the label layout may include displaying the drug name at the top, clinical trial information and test information in the middle, and drug production information and a QR code or barcode at the bottom. Subsequently, key information is extracted from the sample data set, and these key information are encoded as initial sample information of the sample traceability label based on the label layout. These information are associated with the drug trial type and are used to represent the key characteristics of the drug and / or drug trial characteristics. Finally, the sample traceability label is constructed based on the label layout and the initial sample information to ensure that all key information is accurate and displayed on the label in an appropriate format. The constructed sample traceability label may be as follows:
[0052] Drug name: Anticancer drug X;
[0053] Clinical trial number: CT2024-001;
[0054] Trial phase: Phase III;
[0055] Trial type: Randomized controlled, double-blind;
[0056] Test items: blood routine, liver function, kidney function, once every two weeks;
[0057] Production batch number: B12345;
[0058] Production date: 2024-01-01;
[0059] Valid until: 2026-01-01;
[0060] [QR code]
[0061] The QR code can contain the encoded data of all text information so that all key information can be quickly obtained by scanning. Through the above steps, a complete sample traceability label can be generated to ensure the full traceability and information transparency of drugs in clinical trials.
[0062] As an optional embodiment, in 202, determining the label layout of the sample traceability label based on the sample information may be implemented as follows:
[0063] 301, identifying the drug type of the target drug based on the sample information; the drug type includes at least chemical drugs, biological drugs, and traditional Chinese medicine;
[0064] 302, determining the label information category and information density of the sample traceability label based on the drug type; wherein the information density is used to determine the information display position and the distribution position of the information display position in the sample traceability label;
[0065] 303 : Generate a label layout of the sample traceability label according to the label information category and the information density.
[0066] Exemplarily, in 202, first, the drug type to which the target drug belongs is identified based on the sample information, and these drug types include at least chemical drugs, biological drugs and traditional Chinese medicine. For example, if the sample information shows that the target drug is an antibody drug, it is identified as a biological drug. Next, the label information category and information density of the sample traceability label are determined based on the drug type, wherein the information density is used to determine the information display positions in the sample traceability label and the distribution positions of these display positions. For example, for chemical drugs, the label information category may mainly include drug name, chemical composition, clinical trial stage, production batch, etc., with a high information density, requiring more detailed information to be displayed in the label, and the distribution of each information display position may be relatively compact. For traditional Chinese medicine, the label information category may focus on the source of medicinal materials, production process, clinical use, etc., with a relatively low information density, and the distribution of information display positions can be more dispersed and concise. Finally, the label layout of the sample traceability label is generated according to the label information category and information density. For example, for biological drugs, the label layout may be designed to display the drug name and drug type at the top, clinical trial information and production batch information in the middle, and production date, expiration date and QR code at the bottom. This layout ensures that the key information of biopharmaceuticals is effectively presented and meets the logical and aesthetic requirements of label design.
[0067] Further optionally, if the drug type is a chemical drug, the label information category includes at least the drug name, production batch number, test type, test equipment number, drug instructions, drug test progress, and drug test data.
[0068] For example, for a chemical drug, such as antibiotic C, the label information category of the drug should include at least the following:
[0069] Drug name: Antibiotic C;
[0070] Production batch number: CH2024-0456;
[0071] Trial type: Phase III clinical trial, randomized controlled, double-blind trial;
[0072] Test equipment number: EQ123456;
[0073] Instructions for use: 500 mg each time, three times a day, after meals;
[0074] Drug trial progress: Currently in the 5th month interim analysis phase;
[0075] Drug trial data: Preliminary data show that the efficacy against bacterial infections is 85%;
[0076] If the drug type is a biological drug, the label information category includes at least the drug name, production batch number, production date, expiration date, storage conditions, test type, test equipment number, drug instructions, drug test progress, and drug test data.
[0077] For example, for a biological drug, such as monoclonal antibody drug Y, the label information category of the drug should include at least the following:
[0078] Drug name: Monoclonal antibody Y;
[0079] Production batch number: BI2024-0789;
[0080] Production date: 2024-03-15;
[0081] Valid until: 2026-03-15;
[0082] Storage conditions: Refrigerate at 2-8°C, avoid direct sunlight;
[0083] Trial type: Phase III clinical trial, randomized controlled, double-blind trial;
[0084] Test equipment number: EQ654321;
[0085] Instructions for use: 200 mg per injection, once every two weeks;
[0086] Drug trial progress: All patients have been enrolled and efficacy evaluation is ongoing;
[0087] Drug trial data: Preliminary data showed a 60% tumor reduction rate;
[0088] If the drug type is traditional Chinese medicine, the label information category includes at least the drug name, production batch number, medicinal ingredients, processing method, test type, test equipment number, drug instructions, drug test progress, and drug test data.
[0089] For a traditional Chinese medicine, such as Qingrejiedu Granules, the label information category of the drug shall include at least the following:
[0090] Drug name: Qingrejiedu granules;
[0091] Production batch number: TCM2024-1234;
[0092] Medicinal ingredients: honeysuckle, forsythia, scutellaria;
[0093] Processing method: traditional decoction extraction, low temperature drying into powder;
[0094] Trial type: Phase II clinical trial, open-label trial;
[0095] Test equipment number: EQ789123;
[0096] Instructions for use: 10g each time, take with water, three times a day;
[0097] Drug trial progress: Phase II clinical efficacy observation is ongoing;
[0098] Drug trial data: Preliminary data show that it is 75% effective against upper respiratory tract infections;
[0099] The above examples illustrate the specific content of label information categories for different drug types. These information categories are customized according to the characteristics of the drug and the test requirements to ensure the traceability and safety of the drug in clinical trials.
[0100] 103, monitor the real-time test status of the target drug. Specifically, first, establish a real-time data acquisition system that can be connected to various equipment and data management platforms at the clinical trial site to obtain the test status information of the target drug in real time. This information includes but is not limited to the use of the drug during the trial, the operating status of the test equipment, the patient's feedback data, and the update of the drug test data. Secondly, compare the acquired real-time data with the expected progress in the drug test plan to analyze whether the current test status meets expectations. If an abnormal situation is found, such as the drug's test data deviates from the expected value, the test equipment fails, or the patient feedbacks adverse reactions, the system will immediately issue an alarm and generate a corresponding report for reference and decision-making by the research team. Finally, the monitoring results of the real-time test status will be recorded and archived for subsequent analysis and review. These data can also be used to optimize the design of subsequent test stages and improve the efficiency and reliability of drug trials.
[0101] Through such a monitoring mechanism, the real-time status of the target drug in the clinical trial can be effectively managed and controlled, potential problems can be discovered and resolved in a timely manner, and the smooth progress of the trial and the safety of the drug can be ensured.
[0102] As an optional embodiment, the real-time traceability model at least includes the following structures: extraction module, tracing module, and label management module. Specifically, the real-time traceability model is used to analyze the real-time test status of the target drug, and dynamically update and remotely manage the sample traceability label. The model mainly includes the following three structural modules: extraction module, tracing module, and label management module. Optionally, the extraction module is responsible for extracting the test process data and / or test operation data of the target drug from the real-time test status. Through the connection with various test equipment and data management systems, the extraction module can capture key data in the test in real time, such as the use of drugs, equipment operation records, and patient feedback information. After the traceability module extracts the data, the traceability module uses these data to trace the test path of the target drug using a seed genetic algorithm. Through this process, the various stages of the drug in the test process can be recorded and analyzed in detail, so as to obtain the real-time test path of the drug. This path information is of great significance for understanding the progress and effect of the drug test. Based on the real-time test path provided by the traceability module, the label management module dynamically updates the content in the sample traceability label and realizes remote management. For example, if some data are found to be abnormal during the trial, or the trial progresses to a new stage, the label management module can immediately update the label content, such as drug instructions, trial progress, or the latest trial data. At the same time, through the remote management function, researchers can view and manage these labels in real time at different locations to ensure the accuracy and timeliness of trial information.
[0103] Further, based on the above structure, the real-time traceability model is used in 104 to analyze the real-time test status, and the sample traceability label is dynamically updated and / or remotely managed, which can be implemented as follows:
[0104] 401, extracting the test process data and / or test operation data of the target drug in the real-time test state through an extraction module;
[0105] 402, using a traceability module, based on the test process data and / or the test operation data, using a seed genetic algorithm to trace the test path of the target drug, so as to obtain a real-time test path of the target drug;
[0106] 403 , dynamically updating and / or remotely managing the real-time label content in the sample traceability label based on the real-time test path through a label management module.
[0107] In 104, the real-time traceability model is used to analyze the real-time test status, and the sample traceability label is dynamically updated and / or remotely managed. In 401, the test process data and / or test operation data of the target drug are obtained from the real-time test status through the extraction module. These data may include drug usage records, the operating status of the test equipment, patient feedback information, etc. In 402, the test path of the target drug is traced through the traceability module based on the extracted test process data and / or test operation data. This process will generate a real-time test path for the target drug to record the various stages and related data that the drug has experienced in the test. In 403, the content of the sample traceability label is dynamically updated and / or remotely managed using the information of the real-time test path through the label management module. For example, the label management module can automatically adjust the information on the label according to the latest test data, and remotely update the relevant label content through the network to ensure that the test team and relevant personnel can obtain the latest drug test status in real time.
[0108] This real-time traceability model ensures the traceability of drug trials and the real-time nature of data, making the entire trial process more transparent and efficient.
[0109] As an optional embodiment, the real-time traceability model also includes: a test path optimization module. Specifically, the test path optimization module is a component for analyzing and optimizing the drug test path. It optimizes and evaluates each label content object (such as drug instructions, test progress, test data, etc.) by analyzing the initial path data generated during the test process, thereby improving the overall efficiency of the test and the reliability of the data. The introduction of this module aims to optimize the test path to further improve the efficiency and accuracy of the test process. The functions of this module and its specific implementation in steps 404 and 405 will be introduced in detail below.
[0110] Based on the above structure, further, in 402, after the test path of the target drug is traced by the tracing module based on the test process data and / or the test operation data, the seed genetic algorithm is used to obtain the real-time test path of the target drug, and the following steps can be implemented:
[0111] 404, using a test path optimization module and a path optimization model to optimize and analyze each label content object in the initial test path to obtain an optimization score for each label content object; and
[0112] 405 : constructing real-time tag content of each tag content object in the initial trial path based on the optimization score of each tag content object.
[0113] Specifically, in 404, through the test path optimization module, the path optimization model is used to optimize and analyze each label content object in the initial test path. These label content objects may include instructions for use of drugs, test equipment status, test progress information, patient feedback data, etc. The core of the optimization analysis is to evaluate the performance and role of each label content object in the test path, such as its impact on the test results, the accuracy and timeliness of the data, etc. In order to conduct effective optimization analysis, the module can use various data analysis methods and algorithms, such as seed genetic algorithms, machine learning algorithms, etc., to score each label content object and generate an optimization score.
[0114] Through the above analysis process, the test path optimization module generates an optimization score for each label content object. This score reflects the performance quality and optimization potential of the label content object. The higher the score, the more optimized the content object is, and the more conducive it is to the smooth progress of the experiment.
[0115] Based on the optimization scores of each label content object obtained in step 404, the test path optimization module will optimize and reconstruct the label content in the initial test path. Specifically, in 405, the optimal label content object will be selected according to the optimization score to construct the final real-time label content. These contents will reflect the latest status and optimization results of the drug trial to ensure that the test path achieves the best results in actual operation. Through this optimization process, the test path optimization module ultimately generates more efficient and accurate real-time label content. These label contents will be dynamically updated and can be remotely managed and distributed through the label management module to ensure that the test team can access the latest and most optimized test data at any time.
[0116] By introducing the test path optimization module, the real-time traceability model can not only trace the test paths of drugs, but also further optimize these paths. Steps 404 and 405 improve the efficiency of the test and the accuracy of the data by optimizing the analysis and scoring, thereby ensuring that the entire test process is more scientific and efficient. This optimization process is of great significance for improving the success rate and reliability of drug trials.
[0117] Further optionally, the label content object optimization process of the target drug in the test path optimization module is expressed as the following function:
[0118] ,
[0119] in, Representative The optimized score of the target drug label content object, which contains drug traceability path information, Used to control the amplitude part of the exponential function, Represents an imaginary unit multiples or phase angles, Used to adjust the amplitude and direction of the label content object to affect the amplitude and phase of the optimization result. Represents the real part of the target drug label content object on the complex plane, Represents the imaginary part of the target drug label content object on the complex plane, Express The optimized score result is obtained by adding the rotated label content objects.
[0120] The above formula describes the optimization process of the target drug label content object in the test path optimization module, and optimizes the label content object through mathematical functions, thereby affecting the traceability path in the drug test. Specifically, the real and imaginary parts of the complex plane are used in the formula to represent the different attributes of the target drug label content object. These attributes are combined through complex mathematical relationships to accurately control the traceability path of the drug. By adjusting the amplitude and phase angle in the formula, the drug label content object can be effectively optimized to make the traceability path more reasonable and efficient. Secondly, by using the amplitude part of the exponential function and multiples of its imaginary unit or phase angle, the above formula can dynamically adjust the optimization direction and strength of the label content object. This flexibility enables the optimization process to be adaptively adjusted according to real-time test data, so that the optimal label content configuration can be obtained under different test conditions. Thirdly, the above formula calculates the final optimization score by adding multiple rotated label content objects, which reflects the result of comprehensive consideration of each label content object. This method can effectively balance the relationship between different label content objects, avoid the excessive influence of a single factor on the overall optimization result, and ensure the comprehensiveness and stability of the optimization result. Finally, the complex plane representation method in the above formula makes the optimization process highly stable, avoiding drastic fluctuations in optimization results caused by changes in a single variable. At the same time, the addition of multiple label content objects can ensure the consistency of the optimization process, so that the optimized label content can maintain consistent traceability in different test scenarios. Through this formula, the test path optimization module can manage drug label content objects more intelligently and finely.
[0121] In the embodiment of the present application, a method for managing drugs for clinical trials based on traceability is provided. First, sample information of the target drug is obtained; the sample information includes at least: drug name, clinical trial information, test information, and drug production information. Then, a corresponding sample traceability label is generated based on the sample information; the sample traceability label is at least used to record the sample distribution of the drug test and the real-time test status. Next, the real-time test status of the target drug is monitored; the real-time test status is used to indicate the current progress of the drug test and the real-time test process data during the clinical trial. Finally, the real-time traceability model is used to analyze the real-time test status, dynamically update and / or remotely manage the sample traceability label to ensure that the user obtains the real-time test progress of the target drug. In the embodiment of the present application, sample traceability labels and data records are automatically generated through sample traceability labels and real-time traceability models, reducing errors that may be caused by manual data entry and improving data reliability. In addition, in the embodiment of the present application, the real-time test status is analyzed by the real-time traceability model, and the information on the sample traceability label can be dynamically updated, which helps to obtain the latest test data and progress in a timely manner and improve the transparency and traceability of the test process.
[0122] In another embodiment of the present application, a drug management system for clinical trials based on traceability is also provided. Figure 2 The traceable clinical trial drug management system includes the following units:
[0123] An acquisition unit is configured to acquire sample information of a target drug; the sample information at least includes: drug name, clinical trial information, test information, and drug production information;
[0124] A generating unit is configured to generate a corresponding sample traceability label based on the sample information; the sample traceability label is at least used to record the sample distribution and real-time test status of the drug test;
[0125] A monitoring unit configured to monitor the real-time test status of the target drug; the real-time test status is used to indicate the current progress of the drug test and real-time test process data during the clinical trial;
[0126] The management unit is configured to analyze the real-time test status using a real-time traceability model, dynamically update and / or remotely manage the sample traceability label to ensure that the user obtains the real-time test progress of the target drug.
[0127] Further optionally, the generating unit generates a corresponding sample traceability label based on the sample information, and is configured to:
[0128] Integrate the drug name, clinical trial information, test information, and drug production information in the sample information into a sample data set of the target drug;
[0129] determining a label layout of the sample traceability label based on the sample information;
[0130] Extracting key information from the sample data set, and encoding the key information as initial sample information of the sample traceability label based on the label layout; the key information is associated with a drug test type; the key information is used to represent a key characteristic of a drug and / or a drug test characteristic;
[0131] The sample traceability label is constructed based on the label layout and the initial sample information.
[0132] Further optionally, the generating unit determines the label layout of the sample traceability label based on the sample information, and is configured to:
[0133] Identify the drug type to which the target drug belongs based on the sample information; the drug type includes at least chemical drugs, biological drugs, and traditional Chinese medicine;
[0134] Determining the label information category and information density of the sample traceability label based on the drug type; wherein the information density is used to determine the information display position and the distribution position of the information display position in the sample traceability label;
[0135] A label layout of the sample traceability label is generated according to the label information category and the information density.
[0136] Further optionally, if the drug type is a chemical drug, the label information category includes at least the drug name, production batch number, test type, test equipment number, drug instructions, drug test progress, and drug test data;
[0137] If the drug type is a biological drug, the label information category includes at least the drug name, production batch number, production date, expiration date, storage conditions, test type, test equipment number, drug instructions, drug test progress, and drug test data;
[0138] If the drug type is traditional Chinese medicine, the label information category includes at least the drug name, production batch number, medicinal ingredients, processing method, test type, test equipment number, drug instructions, drug test progress, and drug test data.
[0139] Further optionally, the real-time traceability model at least includes the following structures: an extraction module, a tracing module, and a label management module; a management unit, which uses the real-time traceability model to analyze the real-time test status, dynamically updates and / or remotely manages the sample traceability label, and is configured as follows:
[0140] Extracting the test process data and / or test operation data of the target drug in the real-time test state through the extraction module;
[0141] Through the traceability module, based on the test process data and / or test operation data, the seed genetic algorithm is used to trace the test path of the target drug to obtain the real-time test path of the target drug;
[0142] Through the label management module, based on the real-time test path, the real-time label content in the sample traceability label is dynamically updated and / or remotely managed.
[0143] Further optionally, the real-time traceability model further includes: a test path optimization module; a management unit, which, through the traceability module, traces the test path of the target drug using a seed genetic algorithm based on the test process data and / or the test operation data to obtain the real-time test path of the target drug, is further configured to:
[0144] By using a test path optimization module, optimizing and analyzing each label content object in the initial test path using a path optimization model, and obtaining an optimization score for each label content object; and
[0145] Based on the optimized scores of the respective label content objects, real-time label content of the respective label content objects in the initial trial path is constructed.
[0146] Further optionally, the label content object optimization process of the target drug in the test path optimization module is expressed as the following function:
[0147] ,
[0148] in, Representative The optimized score of the target drug label content object, which contains drug traceability path information, Used to control the amplitude part of the exponential function, Represents an imaginary unit multiples or phase angles, Used to adjust the amplitude and direction of the label content object to affect the amplitude and phase of the optimization result. Represents the real part of the target drug label content object on the complex plane, Represents the imaginary part of the target drug label content object on the complex plane, Express The optimized score result is obtained by adding the rotated label content objects.
[0149] The system can implement various steps in the above method embodiment, which will not be expanded here.
[0150] In the embodiments of the present application, sample traceability labels and data records can be automatically generated through sample traceability labels and real-time traceability models, thereby reducing errors that may be caused by manual data entry, improving data reliability, and improving the transparency and traceability of the test process.
[0151] See also Figure 3 , Figure 3 Schematic diagram of an electronic device provided by an embodiment of the present invention. Figure 3 As shown, an embodiment of the present invention provides an electronic device 500, including a memory 510, a processor 520, and a computer program 511 stored in the memory 510 and executable on the processor 520. When the processor 520 executes the computer program 511, the following steps are implemented: obtaining sample information of a target drug; the sample information at least includes: drug name, clinical trial information, test detection information, and drug production information; generating a corresponding sample traceability label based on the sample information; the sample traceability label is at least used to record the sample distribution of the drug trial and the real-time test status; monitoring the real-time test status of the target drug; the real-time test status is used to indicate the current progress of the test of the target drug during the clinical trial and the real-time test process data; using a real-time traceability model to analyze the real-time test status, dynamically update and / or remotely manage the sample traceability label to ensure that the user obtains the real-time test progress of the target drug.
[0152] See also Figure 4 , Figure 4 A schematic diagram of an embodiment of a computer-readable storage medium provided in an embodiment of the present invention. Figure 4As shown, this embodiment provides a computer-readable storage medium 600, on which a computer program 611 is stored. When the computer program 611 is executed by a processor, the following steps are implemented: obtaining sample information of a target drug; the sample information at least includes: drug name, clinical trial information, test detection information, and drug production information; generating a corresponding sample traceability label based on the sample information; the sample traceability label is at least used to record the sample distribution of the drug trial and the real-time trial status; monitoring the real-time trial status of the target drug; the real-time trial status is used to indicate the current progress of the trial of the target drug during the clinical trial and the real-time trial process data; using a real-time traceability model to analyze the real-time trial status, dynamically update and / or remotely manage the sample traceability label to ensure that the user obtains the real-time trial progress of the target drug.
[0153] It should be noted that in the above embodiments, the description of each embodiment has its own emphasis, and for parts that are not described in detail in a certain embodiment, reference can be made to the relevant descriptions of other embodiments.
[0154] It will be appreciated by those skilled in the art that embodiments of the present invention may be provided as methods, systems, or computer program products. Therefore, the present invention may take the form of a complete hardware embodiment, a complete software embodiment, or an embodiment combining software and hardware. Furthermore, the present invention may take the form of a computer program product implemented on one or more computer-usable storage media (including but not limited to disk storage, CD-ROM, optical storage, etc.) containing computer-usable program code.
[0155] The present invention is described with reference to flowcharts and / or block diagrams of methods, devices (systems), and computer program products according to embodiments of the present invention. It should be understood that each process and / or block in the flowchart and / or block diagram, as well as the combination of processes and / or blocks in the flowchart and / or block diagram, can be implemented by computer program instructions. These computer program instructions can be provided to a processor of a general-purpose computer, a special-purpose computer, an embedded computer, or other programmable data processing device to produce a machine, so that the instructions executed by the processor of the computer or other programmable data processing device generate instructions for implementing the processes in the flowchart and / or block diagram. Figure 1 A process or multiple processes and / or boxes Figure 1 A device that provides the functions specified in a block or multiple blocks.
[0156] These computer program instructions may also be stored in a computer-readable memory capable of directing a computer or other programmable data processing device to operate in a specific manner, so that the instructions stored in the computer-readable memory produce an article of manufacture comprising an instruction device, which implements the process Figure 1 A process or multiple processes and / or boxes Figure 1A function specified in one or more boxes.
[0157] These computer program instructions can also be loaded onto a computer or other programmable data processing device so that a series of operating steps are executed on the computer or other programmable device to produce a computer-implemented process, thereby providing instructions for implementing the process. Figure 1 A process or multiple processes and / or boxes Figure 1 The steps for the functions specified in one or more boxes.
[0158] Although the preferred embodiments of the present invention have been described, those skilled in the art may make other changes and modifications to these embodiments once they have learned the basic creative concept. Therefore, the appended claims are intended to be interpreted as including the preferred embodiments and all changes and modifications that fall within the scope of the present invention.
[0159] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.
Claims
1. A method for managing drugs for clinical trials based on traceability, characterized in that: The method comprises: Obtain sample information of the target drug; the sample information includes at least: drug name, clinical trial information, test information, and drug production information; Generate a corresponding sample traceability label based on the sample information; the sample traceability label is at least used to record the sample distribution and real-time test status of the drug test; Monitor the real-time test status of the target drug; the real-time test status is used to indicate the current progress of the test of the target drug during the clinical trial and real-time test process data; A real-time traceability model is used to analyze the real-time test status, and the sample traceability label is dynamically updated and / or remotely managed to ensure that the user obtains the real-time test progress of the target drug; The generating a corresponding sample traceability label based on the sample information includes: Integrate the drug name, clinical trial information, test information, and drug production information in the sample information into a sample data set of the target drug; determining a label layout of the sample traceability label based on the sample information; Extracting key information from the sample data set, and encoding the key information as initial sample information of the sample traceability label based on the label layout; the key information is associated with a drug test type; the key information is used to represent a key characteristic of a drug and / or a drug test characteristic; constructing the sample traceability label based on the label layout and the initial sample information; The real-time traceability model includes at least the following structures: extraction module, tracing module, and label management module; The real-time traceability model is used to analyze the real-time test status, and the sample traceability label is dynamically updated and / or remotely managed, including: Extracting the test process data and / or test operation data of the target drug in the real-time test state through the extraction module; Through the traceability module, based on the test process data and / or test operation data, the seed genetic algorithm is used to trace the test path of the target drug to obtain the real-time test path of the target drug; Dynamically updating and / or remotely managing the real-time label content in the sample traceability label based on the real-time test path through a label management module; The real-time traceability model also includes: a test path optimization module; After the test path of the target drug is traced by the tracing module based on the test process data and / or the test operation data using the seed genetic algorithm to obtain the real-time test path of the target drug, the method further includes: Through the test path optimization module, the path optimization model is used to optimize and analyze each label content object in the initial test path to obtain an optimization score for each label content object; and Based on the optimized scores of the respective label content objects, constructing the real-time label content of the respective label content objects in the initial test path; The label content object optimization process of the target drug in the test path optimization module is expressed as the following function: ; in, Representative The optimized score of the target drug label content object, which contains drug traceability path information, Used to control the amplitude part of the exponential function, Represents an imaginary unit multiples or phase angles, Used to adjust the amplitude and direction of the label content object to affect the amplitude and phase of the optimization result. Represents the real part of the target drug label content object on the complex plane, Represents the imaginary part of the target drug label content object on the complex plane, Express The optimized score result is obtained by adding the rotated label content objects.
2. The method for managing drugs for clinical trials based on traceability according to claim 1, characterized in that: The step of determining the label layout of the sample traceability label based on the sample information includes: Identify the drug type to which the target drug belongs based on the sample information; the drug type includes at least chemical drugs, biological drugs, and traditional Chinese medicine; Determining the label information category and information density of the sample traceability label based on the drug type; wherein the information density is used to determine the information display position and the distribution position of the information display position in the sample traceability label; A label layout of the sample traceability label is generated according to the label information category and the information density.
3. The method for managing drugs for clinical trials based on traceability according to claim 2, characterized in that: If the drug type is a chemical drug, the label information category includes at least the drug name, production batch number, test type, test equipment number, drug instructions, drug test progress, and drug test data; If the drug type is a biological drug, the label information category includes at least the drug name, production batch number, production date, expiration date, storage conditions, test type, test equipment number, drug instructions, drug test progress, and drug test data; If the drug type is traditional Chinese medicine, the label information category includes at least the drug name, production batch number, medicinal ingredients, processing method, test type, test equipment number, drug instructions, drug test progress, and drug test data.
4. A drug management system for clinical trials based on traceability, characterized in that: The system comprises the following units, wherein: An acquisition unit is configured to acquire sample information of a target drug; the sample information at least includes: drug name, clinical trial information, test information, and drug production information; A generating unit configured to generate a corresponding sample traceability label based on the sample information; the sample traceability label is at least used to record the sample distribution and real-time test status of the drug test; A monitoring unit configured to monitor the real-time test status of the target drug; the real-time test status is used to indicate the current progress of the drug test and real-time test process data during the clinical trial; A management unit configured to analyze the real-time test status using a real-time traceability model, dynamically update and / or remotely manage the sample traceability label to ensure that the user obtains the real-time test progress of the target drug; The generating a corresponding sample traceability label based on the sample information includes: Integrate the drug name, clinical trial information, test information, and drug production information in the sample information into a sample data set of the target drug; determining a label layout of the sample traceability label based on the sample information; Extracting key information from the sample data set, and encoding the key information as initial sample information of the sample traceability label based on the label layout; the key information is associated with a drug test type; the key information is used to represent a key characteristic of a drug and / or a drug test characteristic; constructing the sample traceability label based on the label layout and the initial sample information; The real-time traceability model includes at least the following structures: extraction module, tracing module, and label management module; The real-time traceability model is used to analyze the real-time test status, and the sample traceability label is dynamically updated and / or remotely managed, including: Extracting the test process data and / or test operation data of the target drug in the real-time test state through the extraction module; Through the traceability module, based on the test process data and / or test operation data, the seed genetic algorithm is used to trace the test path of the target drug to obtain the real-time test path of the target drug; Dynamically updating and / or remotely managing the real-time label content in the sample traceability label based on the real-time test path through a label management module; The real-time traceability model also includes: a test path optimization module; After the test path of the target drug is traced by the tracing module based on the test process data and / or the test operation data using the seed genetic algorithm to obtain the real-time test path of the target drug, the method further includes: Through the test path optimization module, the path optimization model is used to optimize and analyze each label content object in the initial test path to obtain an optimization score for each label content object; and Based on the optimized scores of the respective label content objects, constructing the real-time label content of the respective label content objects in the initial test path; The label content object optimization process of the target drug in the test path optimization module is expressed as the following function: ; in, Representative The optimized score of the target drug label content object, which contains drug traceability path information, Used to control the amplitude part of the exponential function, Represents an imaginary unit multiples or phase angles, Used to adjust the amplitude and direction of the label content object to affect the amplitude and phase of the optimization result. Represents the real part of the target drug label content object on the complex plane, Represents the imaginary part of the target drug label content object on the complex plane, Express The optimized score result is obtained by adding the rotated label content objects.
Citation Information
Patent Citations
Data processing system and method based on drug clinical test quality specifications
CN112951365A
Drug traceable management system
CN117132298A
